Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 14.3%Very low 6 · 85.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Potent vs moderate‐potency topical corticosteroid

Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 99 participants
Very low

Very potent vs potent topical corticosteroid

Systemic adverse events: abnormal cortisol · adults with eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 117 participants
Very low

Twice daily or more vs once daily topical corticosteroid

Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 249 participants
Very low

Longer‐term vs shorter‐term duration of use of topical corticosteroid

Systemic adverse events at · people with eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Weekend therapy vs no topical corticosteroids

Systemic adverse events: abnormal cortisol; end of treatment (16 weeks + 4 weeks acute phase) · children and adults with mild to severe eczema

It is very uncertain whether weekend therapy changes systemic adverse events: abnormal cortisol; end of treatment (16… compared with no topical corticosteroid (very low certainty).

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 5 participants
Very low

Moderate‐potency vs mild‐potency topical corticosteroid

Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema

It is very uncertain whether moderate‐potency changes systemic adverse events: abnormal cortisol; end of treatment (6‐28… compared with mild‐potency topical corticosteroid (very low certainty).

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 33 participants
Very low

Potent vs mild‐potency topical corticosteroid

Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 82 participants
Very low